Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Redefining Non-Inferiority in Anamnestic Antibody Responses Using the Mean Increase of Log-Transformed Antibody Titers after Revaccination: Secondary Analysis of a Randomized Controlled Rabies Vaccination Trial.
Overduin LA, Soentjens PHP, Goeman JJ, Berkowska MA, van Dongen JJM, Visser LG. Overduin LA, et al. Among authors: visser lg. Vaccines (Basel). 2020 Dec 2;8(4):721. doi: 10.3390/vaccines8040721. Vaccines (Basel). 2020. PMID: 33276423 Free PMC article.
Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2-specific CD8+ T cell responses following COVID-19.
Roukens AHE, Pothast CR, König M, Huisman W, Dalebout T, Tak T, Azimi S, Kruize Y, Hagedoorn RS, Zlei M, Staal FJT, de Bie FJ, van Dongen JJM, Arbous SM, Zhang JLH, Verheij M, Prins C, van der Does AM, Hiemstra PS, de Vries JJC, Janse JJ, Roestenberg M, Myeni SK, Kikkert M, Yazdanbakhsh M, Heemskerk MHM, Smits HH, Jochems SP; in collaboration with BEAT-COVID group; in collaboration with COVID-19 LUMC group. Roukens AHE, et al. Nat Immunol. 2022 Jan;23(1):23-32. doi: 10.1038/s41590-021-01095-w. Epub 2021 Dec 22. Nat Immunol. 2022. PMID: 34937933
Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial.
Prins MLM, Roozen GVT, Pothast CR, Huisman W, van Binnendijk R, den Hartog G, Kuiper VP, Prins C, Janse JJ, Lamers OAC, Koopman JPR, Kruithof AC, Kamerling IMC, Dijkland RC, de Kroon AC, Azimi S, Feltkamp MCW, Kuijer M, Jochems SP, Heemskerk MHM, Rosendaal FR, Roestenberg M, Visser LG, Roukens AHE. Prins MLM, et al. Among authors: visser lg. NPJ Vaccines. 2024 Jan 2;9(1):1. doi: 10.1038/s41541-023-00785-w. NPJ Vaccines. 2024. PMID: 38167735 Free PMC article.
Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study.
Roukens AH, Soonawala D, Joosten SA, de Visser AW, Jiang X, Dirksen K, de Gruijter M, van Dissel JT, Bredenbeek PJ, Visser LG. Roukens AH, et al. Among authors: visser lg. PLoS One. 2011;6(12):e27753. doi: 10.1371/journal.pone.0027753. Epub 2011 Dec 7. PLoS One. 2011. PMID: 22163273 Free PMC article. Clinical Trial.
A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after Vaccination.
Wieten RW, Jonker EF, van Leeuwen EM, Remmerswaal EB, Ten Berge IJ, de Visser AW, van Genderen PJ, Goorhuis A, Visser LG, Grobusch MP, de Bree GJ. Wieten RW, et al. Among authors: visser lg. PLoS One. 2016 Mar 15;11(3):e0149871. doi: 10.1371/journal.pone.0149871. eCollection 2016. PLoS One. 2016. PMID: 26977808 Free PMC article.
242 results